FIELD: biotechnology.
SUBSTANCE: invention discloses an antibody against properdin or an antigen-binding portion thereof and an immunoconjugate containing them. Also disclosed is a composition containing said antibody or antigen-binding portion thereof. Invention also relates to a nucleic acid coding said antibody, an expression vector and a host cell containing said nucleic acid. Antibody can be used to prepare a drug for treating diseases mediated by a component of the alternative complement pathway and/or a factor formed after activation of the alternative complement pathway.
EFFECT: antibody of the present invention leads to selective inhibition of the alternative complement pathway, while allowing the classical and lectin pathways to be continued.
18 cl, 10 dwg, 8 tbl, 19 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODIES AND THEIR APPLICATIONS | 2022 |
|
RU2821577C2 |
| CHIMERIC CYTOKINE RECEPTORS CARRYING PD-1 ECTODOMAIN | 2020 |
|
RU2828214C2 |
| MONOCLONAL ANTIBODIES AGAINST THE RECEPTOR-BINDING DOMAIN OF SARS-COV-2 SPIKE PROTEIN AND THEIR ANTIGEN-BINDING FRAGMENTS ENCODING THEIR NUCLEIC ACIDS, AS WELL AS METHODS OF THEIR USE | 2021 |
|
RU2800649C2 |
| MONOCLONAL ANTIBODY IC2 AND ITS ANTIGEN-BINDING FRAGMENT, SELECTIVELY BINDING RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 VIRUS, HAVING VIRUS-NEUTRALIZING ACTIVITY | 2023 |
|
RU2817697C1 |
| MONOCLONAL ANTIBODY IC1 AND ITS ANTIGEN-BINDING FRAGMENT, SELECTIVELY BINDING RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 VIRUS, HAVING VIRUS-NEUTRALIZING ACTIVITY | 2023 |
|
RU2817696C1 |
| MUS MUSCULUS 5B9 HYBRID CULTIVATED ANIMAL CELLS- A PRODUCER OF MOUSE MONOCLONAL ANTIBODY 5B9, MONOCLONAL MOUSE ANTIBODY 5B9 AND RECOMBINANT CHIMERIC (MOUSE-HUMAN) ANTIBODY XI5B9, NEUTRALIZING RICIN RICINUS COMMUNIS | 2022 |
|
RU2802436C1 |
| BCMA-SPECIFIC CHIMERIC ANTIGEN RECEPTORS CONTAINING IL-6 SIGNALLING BLOCKER | 2023 |
|
RU2828294C1 |
| MONOCLONAL ANTIBODIES SPECIFIC TO PROTEIN RUSTICYANIN, AND USE OF ANTIBODIES FOR DIAGNOSIS AND TREATMENT OF MALIGNANT NEOPLASMS | 2024 |
|
RU2823344C1 |
| NUCLEOTIDE SEQUENCE CODING LYTICASE ENZYME, AND PANEL OF OLIGONUCLEOTIDES FOR OBTAINING SYNTHETIC NUCLEOTIDE SEQUENCE OF LYTICASE GENE | 2023 |
|
RU2826150C1 |
| METHOD OF PRODUCING MOUSE MODEL FOR STUDYING DUCHENNE MUSCULAR DYSTROPHY AND VERSIONS OF ITS THERAPY | 2023 |
|
RU2815936C1 |
